Form 4: OmniAb Chief Legal Officer Reports Stock Transactions Following PSU Vesting

OmniAb's Chief Legal Officer, Charles S. Berkman, acquired shares through performance stock unit vesting and sold a portion to cover tax obligations.

Summary

• Charles S. Berkman, Chief Legal Officer of OmniAb, Inc., reported transactions involving the company's common stock.
• On January 17, 2025, Mr. Berkman acquired 45,294 shares of common stock upon the vesting of performance stock units (PSUs).
• These PSUs were granted on July 5, 2022, and vested based on the company's performance through December 31, 2024.
• On January 21, 2025, Mr. Berkman sold 25,489 shares at a weighted average price of $3.24 per share to cover tax withholding obligations.
• The sales occurred in multiple transactions with prices ranging from $3.21 to $3.27.
• Following these transactions, Mr. Berkman beneficially owns 343,190 shares of OmniAb common stock.

Sentiment

Score: 6

Explanation: The document reflects standard executive stock transactions following vesting of performance units. While the sale of shares could be perceived negatively, it is a mandated sell-to-cover transaction for tax purposes, which is a common practice. Therefore, the sentiment is neutral to slightly positive.

Positives

• The vesting of performance stock units indicates that the company met certain performance objectives.
• The sell-to-cover transaction ensures that tax obligations are met without requiring the executive to use personal funds.

Negatives

• The sale of shares by the Chief Legal Officer, even for tax purposes, could be perceived negatively by some investors.

Risks

• The sale of shares by an executive, even for tax purposes, could create short-term selling pressure on the stock.
• The company's performance objectives are not detailed in this document, so it is difficult to assess the quality of the performance.

Management Comments

• The sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell-to-cover' transaction and do not represent discretionary trades by the reporting person.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when executives trade company stock. The vesting of PSUs is a typical form of executive compensation.

Comparison to Industry Standards

• The use of performance stock units (PSUs) as part of executive compensation is a common practice in the biotechnology and pharmaceutical industries, similar to companies like Regeneron Pharmaceuticals and Amgen.
• The 'sell-to-cover' mechanism for tax obligations is also a standard practice, ensuring executives do not need to use personal funds to cover taxes on vested equity, similar to practices at companies like Gilead Sciences and Biogen.
• The reported share price range of $3.21 to $3.27 is within the typical trading range for a company of this size and stage, but without further context, it's difficult to compare to specific peers.

Stakeholder Impact

• Shareholders may be interested in the details of executive compensation and stock transactions.
• Employees may be interested in the vesting of performance stock units as it relates to their own compensation.

Key Dates

Keywords

OmniAb, OABI, Charles S. Berkman, performance stock units, PSUs, stock vesting, insider trading, SEC Form 4, tax withholding, sell-to-cover